If you have been reading about Certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-01. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
== Overview == The first observation of cellular structures resulting from the freezing of water goes back over a century, but the first reported instance of freeze-casting, in the modern sense, was in 1954 when Maxwell et al. attempted to fabricate turbosupercharger blades out of refractory powders. They froze extremely thick slips of titanium carbide, producing near-net-shape castings that were easy to sinter and machine. The goal of this work, however, was to make dense ceramics. It was not until 2001, when Fukasawa et al. created directionally porous alumina castings, that the idea of using freeze-casting as a means of creating novel porous structures really took hold. Since that time, research has grown considerably with hundreds of papers coming out within the last decade. The principles of freeze casting are applicable to a broad range of combinations of particles and suspension media. Water is by far the most commonly used suspension media, and by freeze drying is readily conducive to the step of sublimation that is necessary for the success of freeze-casting processes. Due to the high level of control and broad range of possible porous microstructures that freeze-casting can produce, the technique has been adopted in disparate fields such as tissue scaffolds, photonics, metal-matrix composites, dentistry, materials science, and even food science. There are three possible end results to uni-directionally freezing a suspension of particles. First, the ice-growth proceeds as a planar front, pushing particles in front like a bulldozer pushes a pile of rocks.
===== MeSH D08.811.464.257 – carbon-carbon ligases (EC 6.4) ===== MeSH D08.811.464.257.050 – acetyl-coa carboxylase MeSH D08.811.464.257.275 – polyketide synthases MeSH D08.811.464.257.500 – pyruvate carboxylase
==== Appeal ==== In March 1996 Rose announced her intention to appeal against her sentence, contending that extensive press coverage had rendered witness testimony unreliable, that no physical evidence existed to attest she had participated in any of the murders, that the final instructions delivered by the judge to the jury had been biased in favour of the prosecution, and that undue weight had been given to the similar fact evidence introduced at her trial. This appeal was rejected by the Lord Chief Justice, Lord Taylor of Gosforth, who contended Rose had received a fair trial and efficient legal representation. In July 1997 then-Home Secretary Jack Straw subjected Rose to a whole life tariff, effectively denying her any possibility of parole. In October 2000, Rose again announced that she would appeal against her sentence via her solicitor, Leo Goatley. In September 2001 she announced her intention to abandon her appeals, stating she would never feel free even if released. She maintains her innocence in any of the murders.
Sources: en.wikipedia.org
Kingston Pike saw a boom in tourism in the 1930s and 1940s as it lay along a merged stretch of two cross-country tourism routes, the Dixie Highway and the Lee Highway. During the same period, traffic to the Smokies led to development along Chapman Highway (named for the park's chief promoter, David Chapman) in South Knoxville. In the late 1920s, General Lawrence Tyson donated land off Kingston Pike for McGhee Tyson Airport, named for his son, World War I aviator Charles McGhee Tyson (the airport has since moved to Blount County). In 1947, Knoxville replaced its streetcar system with buses. TVA's completion of Fort Loudoun Dam in 1943 brought modifications to Knoxville's riverfront. In 1946, travel writer John Gunther visited Knoxville, and dubbed the city, the "ugliest city" in America. He also mocked its puritanical laws regarding liquor sales and the showing of movies on Sunday, and noted the city's relatively high crime rate. While Knoxvillians vigorously defended their city, Gunther's comments nevertheless sparked discussions regarding the city's unsightliness and its blue laws. The ordinance forbidding the showing of movies on Sunday was done away with in 1946, with the help of the state legislature. Knoxville legalized packaged liquor in 1961, though the issue remained a contentious one for years.
== Advocacy == AMP advocates for molecular professionals and the patients they serve. In the U.S. molecular genetics testing is governed by a wide range of regulations, including the Clinical Laboratory Improvement Act (CLIA), the Centers for Medicare and Medicaid, and the Food and Drug Administration, that impact the performance and reimbursement of medical laboratory services. Through its advocacy efforts, such as the AMP Economics Summit, AMP strives to modernize the regulatory environment. It works to inform the U.S. Congress and federal agencies regarding public policy issues affecting molecular pathology. AMP seeks to shape and promote policies that ensure broad and equitable patient access to appropriate laboratory testing. Internationally, AMP members are involved in advocating for appropriate molecular diagnostic testing in several countries around the world.
In the eocyte hypothesis linking the closest known archaeal relatives of eukaryotes (achaean eocytes), the organism at the root of the eocytes lineage may have been a ribocyte from the RNA-world. For cellular DNA and DNA processing systems, an "out of virus" scenario has been proposed. In this model, DNA as the main genetic information material may have first evolved in viruses and was later transferred to ribocytes twice: once transforming them into bacteria and once transforming them into archaea. Similarly in viral eukaryogenesis, a hypothesis theorizing that eukaryotes evolved from a DNA virus, ribocytes may have been an ancient host for a DNA virus. Because ribocytes used RNA to store their genetic information, viruses may initially have used DNA as a way to resist RNA-degrading enzymes present in the host ribocells. The introduction of a DNA-based system may have been as significant for protocells as later additions of chloroplasts or mitochondria through endosymbiosis in evolving eukaryotic cells. In this hypothesis, bacteria, archaea, and eukaryotes each obtained their DNA informational system from a different virus. In the reduction hypothesis, where giant viruses evolved from primordial cells that became parasitic, viruses might have evolved after FUCA but before LUCA.
It was proposed by the researchers that low maximal receptor activation, or lower-efficacy partial agonism, could explain the atypical effects of biased MOR agonists like SR-17018 rather than biased agonism. These results were subsequently reanalyzed and disputed by other researchers. In any case, the exact mechanisms underlying the atypical effects of SR-17018 remain unclear. For example, they may be related to G protein over β-arrestin2 bias, or to differences in G protein-mediated signaling. SR-17018 produces rewarding effects as assessed by conditioned place preference (CPP) in rodents. Its rewarding effects in this assay were comparable to those of morphine. In addition to rewarding effects, SR-17018 produces modest hyperlocomotion in rodents, albeit to a far lesser extent than morphine or fentanyl. Addition of SR-17018 to morphine in rodents attenuates morphine-induced hyperlocomotion whilst increasing analgesic efficacy in mice. Unlike morphine and fentanyl, SR-17018 does not produce locomotor sensitization with chronic administration. A self-administration study of SR-17018 in mice was limited by the drug's poor solubility. However, in a subsequent study, the drug produced self-administration in mice, but was less efficacious than oxycodone or fentanyl. SR-17018 has also been found to produce self-administration in rhesus monkeys, but along with buprenorphine, was less efficacious than heroin in this test.
Sources: en.wikipedia.org
== Overview == WHO report released in April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country. Antibiotic resistance—when bacteria change so antibiotics no longer work in people who need them to treat infections—is now a major threat to public health." In 2024, nearly 5 million deaths were associated with AMR and deaths attributable to AMR numbered 1.27 million. One in five people who died due to AMR were children under five years old. In 2018, WHO considered antibiotic resistance to be one of the biggest threats to global health, food security and development. Deaths attributable to AMR vary by area:
ReLEx Small incision lenticule extraction (SMILE), second generation of ReLEx Femtosecond lenticule extraction (FLEx), is a form of laser based refractive eye surgery developed by Carl Zeiss Meditec used to correct myopia, and cure astigmatism. Although similar to LASIK laser surgery, the intrastromal procedure uses a single femtosecond laser referenced to the corneal surface to cleave a thin lenticule from the corneal stroma for manual extraction.
=== Cell cycle regulation === Although preferentially cytosolic, SIRT2 transiently shuttles to the nucleus during the G2/M transition of the cell cycle, where it has a strong preference for histone H4 lysine 16 (H4K16ac), thereby regulating chromosomal condensation during mitosis. During the cell cycle, SIRT2 associates with several mitotic structures including the centrosome, mitotic spindle, and midbody, presumably to ensure normal cell division. Finally, cells with SIRT2 overexpression exhibit marked prolongation of the cell cycle.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.